Universität zu Köln

Dietlein, Felix, Mueller, Peter, Kobe, Carsten, Endepols, Heike, Hohberg, Melanie, Zlatopolskiy, Boris D., Krapf, Philipp, Heidenreich, Axel, Neumaier, Bernd, Drzezga, Alexander and Dietlein, Markus . [F-18]-JK-PSMA-7 PET/CT Under Androgen Deprivation Therapy in Advanced Prostate Cancer. Mol. Imaging. Biol.. NEW YORK: SPRINGER. ISSN 1860-2002

Full text not available from this repository.

Abstract

Purpose PSMA imaging is frequently used for monitoring of androgen deprivation therapy (ADT) in prostate cancer. In a previous study, [F-18]-JK-PSMA-7 exhibited favorable properties for tumor localization after biochemical recurrence. In this retrospective study, we evaluated the performance of [F-18]-JK-PSMA-7 under ADT. Procedures We examined the performance of [F-18]-JK-PSMA-7 in 70 patients (first cohort) with increasing or detectable PSA values under ADT (PSA < 2 ng/ml for 21/70 patients). We further analyzed 58 independent patients with PSA levels < 2 ng/ml under ADT, who were imaged with [Ga-68]PSMA-11 or [F-18]DCFPyL (second cohort). Finally, we compared detection rates between [F-18]-JK-PSMA-7, [Ga-68]PSMA-11, and [F-18]DCFPyL. Results In the first cohort, we detected [F-18]-JK-PSMA-7-positive lesions in 63/70 patients. In patients with PSA levels >= 2 ng/ml, the detection rate was 100 % (49/49). In patients with PSA < 2 ng/ml, the detection rate was significantly lower (66.7 %, 14/21,p= 9.7 x 10(-5)) and dropped from 85.7 % (12/14, PSA levels between 0.3 and 2.0 ng/ml) to 28.6 % (2/7) for PSA levels < 0.3 ng/ml (p= 1.73 x 10(-2)). In the second cohort (PSA < 2 ng/ml), the detection rate was 79.3 % (46/58) for [Ga-68]PSMA-11 or [F-18]DCFPyL. Again, the detection rate was significantly higher (p= 1.1 x 10(-2)) for patients with PSA levels between 0.3 and 2.0 ng/ml (87.0 %, 40/46) relative to those with PSA levels < 0.3 ng/ml (50 %, 6/12). No significant difference was found between [F-18]-JK-PSMA-7 and [Ga-68]PSMA-11 or [F-18]DCFPyL in patients with PSA levels < 2 ng/ml (p= 0.4295). Conclusion [F-18]-JK-PSMA-7 PET showed a high detection rate in patients with PSA levels >= 0.3 ng/ml under ADT. The lower PSA threshold of 0.3 ng/ml for high detection rates was consistent across the three PSMA ligands. Thus, PSMA imaging is suitable for clinical follow-up of patients with increasing PSA levels under ADT.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Dietlein, Felix UNSPECIFIED UNSPECIFIED UNSPECIFIED Mueller, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED Kobe, Carsten UNSPECIFIED UNSPECIFIED UNSPECIFIED Endepols, Heike UNSPECIFIED UNSPECIFIED UNSPECIFIED Hohberg, Melanie UNSPECIFIED UNSPECIFIED UNSPECIFIED Zlatopolskiy, Boris D. UNSPECIFIED UNSPECIFIED UNSPECIFIED Krapf, Philipp UNSPECIFIED UNSPECIFIED UNSPECIFIED Heidenreich, Axel UNSPECIFIED UNSPECIFIED UNSPECIFIED Neumaier, Bernd UNSPECIFIED UNSPECIFIED UNSPECIFIED Drzezga, Alexander UNSPECIFIED UNSPECIFIED UNSPECIFIED Dietlein, Markus UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-317588
DOI:	10.1007/s11307-020-01546-0
Journal or Publication Title:	Mol. Imaging. Biol.
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1860-2002
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language Radiology, Nuclear Medicine & Medical Imaging Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/31758